Genomtec aims for world’s first saliva-based covid test.

EU reviews will be performed at the Dolmed laboratory in Wrocław in May. Reading the test result from the moment the saliva sample is received by the laboratory will be possible after about 15-20 minutes. Genomtech shares on NewConnect increased by over 18% yesterday.

Genomtec has registered and marketed, in the European Union, the diagnostic test Genomtec SARS-Cov-2 EvaGreen Direct-RT-LAMP CE-IVD Kit (RT-LAMP Direct Kit), which allows you to test for the identification of SARS-CoV- infection 2 from the patient’s saliva, the company said.

Registration of a new Genomtec product was possible, among others based on a comparative study carried out at the Central Clinical Hospital of the Ministry of Interior and Administration in Warsaw. The results of Genomtec’s internal research on the test for the diagnosis of SARS-CoV-2 infection directly from the saliva sample indicated that it is one of the lowest detection limits in the world, with only two drops of virus in the reaction mixture, also reported.

Genomtec is an innovative technology company founded in 2016 in Wrocław. Works in the area of ​​molecular diagnostics. The company’s flagship solution is the Genomtec ID mobile diagnostic system, operating on the basis of a microfluidic system and proprietary, patented SNAAT technology. The innovative diagnostic system will be able to carry out several tests simultaneously from one sample, incl. to determine the cause of respiratory infections or sexually transmitted diseases, within 15 minutes. The company is working on several solutions in the field of mobile molecular diagnostics. It also provides research and diagnostic services for enterprises and individual clients. Genomtec made its debut on the NewConnect market in March 2021.


Our privacy policy